ASND
Ascendis Pharma AS
227.90$
+0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 90.6% | 95.4% | 96.8% | 97.0% | 91.8% | 90.3% | 75.5% | 74.3% | 84.7% | 85.1% | 89.9% | 85.1% | |
| 85.5% | 90.8% | 94.9% | 92.6% | 87.1% | 88.4% | 59.7% | 41.1% | 40.8% | 47.5% | 47.4% | 47.3% | |
| 85.5% | 90.8% | 94.9% | 92.6% | 87.1% | 88.4% | 73.4% | 62.9% | 67.5% | 48.4% | 47.4% | 47.3% | |
| 2.2% | 0.8% | 0.2% | 0.1% | 0.0% | 0.1% | 0.0% | 0.2% | 1.1% | 4.3% | 14.1% | 12.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.0% | 12.0% | 25.3% | 25.1% | 23.1% | |
| 4.7% | 1.8% | 1.2% | 1.2% | 1.4% | 6.7% | 11.0% | 11.6% | 11.8% | – | – | – | |
| 6.0% | 2.7% | 1.8% | 1.7% | 1.1% | 0.5% | 0.4% | 0.3% | 0.3% | 0.4% | 0.3% | 0.3% | |
| 6.0% | 2.7% | 158,868.9% | 1.7% | 1.4% | 0.6% | 0.2% | 0.2% | 0.1% | 0.1% | 0.0% | 0.0% | |
| 21.9% | 8.7% | 7.1% | 11.3% | 12.2% | 11.8% | 14.4% | 18.6% | 75.8% | 117.6% | 109.0% | 112.5% | |
| 21.9% | 8.7% | 7.1% | 11.3% | 12.2% | 7.1% | 5.4% | 9.3% | 65.8% | 89.2% | 77.0% | 82.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% | 0.7% | 1.3% | 39.2% | 52.7% | 41.7% | 37.4% | |
| 8.4% | 6.4% | 6.9% | 8.3% | 6.2% | 4.1% | 2.2% | 5.5% | 9.3% | 11.5% | 8.2% | 7.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | 9.0% | 44.3% | 64.7% | 31.0% | 29.6% | |
| 78.1% | 91.3% | 92.9% | 88.7% | 87.8% | 88.2% | 85.6% | 81.4% | 24.2% | -17.6% | -9.0% | -12.5% | |
| 67.4% | 84.4% | -73.3% | -124.8% | -123.3% | -90.3% | -105.2% | -113.9% | -170.7% | -275.8% | -217.0% | -207.3% | |
| 28.9% | 18.0% | 14.0% | 15.9% | 12.9% | 6.9% | 5.2% | 5.0% | 5.1% | 6.8% | 4.9% | 4.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.